

Anti-HER2 (Margetuximab), Chimeric Antibody

01/21

CATALOG NO.: **A2284-50 (50 µg)**
 A2284-100 (100 µg)

BACKGROUND DESCRIPTION: The research-grade biosimilar is a chimeric IgG1 monoclonal antibody targeted against HER2/ERBB2. The original monoclonal antibody is derived from the parent antibody (Trastuzumab). Both antibodies bind efficiently to the same epitope of HER2 and mediate similar effects on cancer cells. However, in contrast to Trastuzumab, the Fc region of this monoclonal antibody is modified to increase the binding to CD16A and reduced binding to CD32B. Increased binding to CD16A leads to increased antibody-dependent cellular cytotoxicity (ADCC). The monoclonal antibody binds to the extracellular domain of HER2 expressed on tumor cells, inhibits tumor growth, and promotes ADCC. The original antibody received FDA approval to treat patients with metastatic HER2 cancer either alone or in combination with chemotherapy.

ALTERNATE NAMES: NEU, NGL, HER2, TKR1, CD340, HER-2, MLN 19; HER-2/neu, ERBB2, EC 2.7.10.1, Herstatin, P185erbB2, EC 2.7.10, MLN19

ANTIBODY TYPE: Monoclonal

HOST/ISOTYPE: Recombinant / IgG1, kappa

SOURCE: CHO cells

IMMUNOGEN: Human HER2

CAS NUMBER: 1350624-75-7

PURIFICATION: Protein A purified

FORM: Liquid

FORMULATION: In PBS, pH 7.5

SPECIES REACTIVITY: Human

STORAGE CONDITIONS: Store at -80°C. Avoid freeze/thaw cycles

This information is only intended as a guide. The optimal dilutions must be determined by the user

RELATED PRODUCTS:

Anti-HER2 Humanized Antibody (A1046)
 Anti-VEGF-A (Brolucizumab), Humanized Antibody (A2221)
 Anti-HER2 (Pertuzumab), Humanized Antibody (A2111)
 Anti-VEGF (Bevacizumab), Humanized Antibody (A1045)
 Anti-EGFR (Panitumumab), Humanized Antibody (A1050)

FOR RESEARCH USE ONLY! Not to be used on humans.